“I worked closely with Kanya on the development of XL765. Kanya was a conscientious and thoughtful medical monitor. I was impressed by her ability to take a concept and turn it quickly into a clinical trial protocol, her ability to relate to investigators, and her integration of information gained from review of the literature into a plan to be implemented. I would welcome the opportunity to work with her again.”
Kanya Rajangam
San Francisco, California, United States
659 followers
500+ connections
San Francisco, California, United States
659 followers
500+ connections
About
Research and development, Clinical development
Activity
-
Turnstone reported today positive initial clinical data from the Phase 1 STARLING trial of TIDAL-01 in metastatic colorectal cancer. Key…
Turnstone reported today positive initial clinical data from the Phase 1 STARLING trial of TIDAL-01 in metastatic colorectal cancer. Key…
Liked by Kanya Rajangam
-
I was thrilled to host the Women in IR and the C-suite Luncheon this week and was delighted by the incredible turnout! Thank you to everyone who…
I was thrilled to host the Women in IR and the C-suite Luncheon this week and was delighted by the incredible turnout! Thank you to everyone who…
Liked by Kanya Rajangam
-
Two Bay Area biotechs — Yael Weiss' rare disease startup Mahzi Therapeutics and cancer-focused Senti Biosciences — win big awards from California's…
Two Bay Area biotechs — Yael Weiss' rare disease startup Mahzi Therapeutics and cancer-focused Senti Biosciences — win big awards from California's…
Liked by Kanya Rajangam
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Recommendations received
1 person has recommended Kanya
Join now to viewMore activity by Kanya
-
Thank you to the terrific Senti Biosciences team and Rochelle Emery, MD for securing the competitive full California Institute for Regenerative…
Thank you to the terrific Senti Biosciences team and Rochelle Emery, MD for securing the competitive full California Institute for Regenerative…
Shared by Kanya Rajangam
-
Thank you to the hard working and terrific Senti Biosciences team- looking forward to seeing what an AML specific targeted (CD33/FLT3) CARNK cell…
Thank you to the hard working and terrific Senti Biosciences team- looking forward to seeing what an AML specific targeted (CD33/FLT3) CARNK cell…
Shared by Kanya Rajangam
-
Big news from Norwest 🎉We’ve launched our $3 billion global fund, NVP 17, to continue partnering with visionary entrepreneurs and teams building the…
Big news from Norwest 🎉We’ve launched our $3 billion global fund, NVP 17, to continue partnering with visionary entrepreneurs and teams building the…
Liked by Kanya Rajangam
-
I was thrilled to present our work at the 2024 AACR Annual Meeting in San Diego! Great to hear about all the exciting science and meet up with…
I was thrilled to present our work at the 2024 AACR Annual Meeting in San Diego! Great to hear about all the exciting science and meet up with…
Liked by Kanya Rajangam
-
On Monday, we’re presenting preclinical data supporting the Phase 1 trial design of SENTI-202, our logic-gated CAR-NK cell therapy for the treatment…
On Monday, we’re presenting preclinical data supporting the Phase 1 trial design of SENTI-202, our logic-gated CAR-NK cell therapy for the treatment…
Liked by Kanya Rajangam
-
Today we announced our financial results for the fourth quarter and full year 2023 and reviewed corporate updates. Learn more:…
Today we announced our financial results for the fourth quarter and full year 2023 and reviewed corporate updates. Learn more:…
Liked by Kanya Rajangam
-
Thank you to Rochelle Samuel and others who hosted a terrific #innatekillersummit2024. It was my honor to moderate the annual industry leaders…
Thank you to Rochelle Samuel and others who hosted a terrific #innatekillersummit2024. It was my honor to moderate the annual industry leaders…
Posted by Kanya Rajangam
-
Academic and popular media writing: Recently, two different pieces of my writing ended up being published around the same time. The simultaneous…
Academic and popular media writing: Recently, two different pieces of my writing ended up being published around the same time. The simultaneous…
Liked by Kanya Rajangam
-
Thank you #IO360 and Michael Kalos for the opportunity to share Senti Biosciences’ plans for SENTI-202 in AML as we enter the clinic this year. Great…
Thank you #IO360 and Michael Kalos for the opportunity to share Senti Biosciences’ plans for SENTI-202 in AML as we enter the clinic this year. Great…
Posted by Kanya Rajangam
-
The people I started Zeck with, we've all had boards. We've sat on boards. And every single time that we went to get ready for the board meeting, we…
The people I started Zeck with, we've all had boards. We've sat on boards. And every single time that we went to get ready for the board meeting, we…
Liked by Kanya Rajangam
-
I am happy to share that I have been awarded the Society For Biomaterials Mid-Career Award! This award was made possible by past and current members…
I am happy to share that I have been awarded the Society For Biomaterials Mid-Career Award! This award was made possible by past and current members…
Liked by Kanya Rajangam
-
🚀 Exciting News 🚀 I’m thrilled to announce a major leap in our journey - acquisition of the (Best in KLAS Research Winner) Value-based Care…
🚀 Exciting News 🚀 I’m thrilled to announce a major leap in our journey - acquisition of the (Best in KLAS Research Winner) Value-based Care…
Liked by Kanya Rajangam
-
Today, we announced the Pfizer acquisition of Seagen has officially closed, marking an exciting new chapter to advance oncology innovation and…
Today, we announced the Pfizer acquisition of Seagen has officially closed, marking an exciting new chapter to advance oncology innovation and…
Liked by Kanya Rajangam
-
Coverage of the TriSalus Phase 1 trial for uveal melanoma with liver metastases, with emphasis on how we are determining the optimal SD-101 dose when…
Coverage of the TriSalus Phase 1 trial for uveal melanoma with liver metastases, with emphasis on how we are determining the optimal SD-101 dose when…
Liked by Kanya Rajangam
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More